

Prostate Biopsy and Targeted Therapy


Nelson N. Stone MD Professor of Urology and Radiation Oncology Mount Sinai School of Medicine, NY, NY


Disclosure

President and CEO 3DBiopsy LLC

Biopsy Techniques 2016 12-core standard transrectal (TRUS) ■1.2 million/year ■ 3.3 million world-wide mpMRI guided transrectal **Transperineal** template guided + mpMRI ■3D-mapping guided

Current Biopsy/Treatment Algorithm





ANTICANCE3 RESEARCE 29: 5155-5162 (2009)

Pathologic Findings in Radical Prostatectomy Specimens From Patients Eligible for Active Surveillance With Highly Selective Criteria: A Multicenter Study

Jean-Baptiste Beauval, Guillaume Ploussard, Michel Soulié, Christian Pfister, Simon Van Agt, Sébastien Vincendeau, Sébastien Larue, Jérome Rigaud, Nicolas Gaschignard, Morgan Rouprêt, Sarah Drouin, Mickael Peyromaure, Jean Alexandre Long, Francois Iborra, Guy Vallancien, Francois Rozet, Laurent Salomon, and Members of Committee of Cancerology of the French Association of Urology (CCAFU)


- Retrospective analysis of 10,785 consecutive radical prostatectomy performed in 10 university hospitals
- 919 patients fulfilled the following criteria:
 - T1c
 - PSA <10 ng/mL
 - 1 positive biopsy, tumor length <3 mm and Gleason score <7.
- Gleason score was upgraded in 34% of patients, including 1.2% Gleason score 8-9. Pathologic stages were pT2 in 87.3%, pT3 in 11.1%, and pT4 in 1.4% of cases. Extraprostatic extension was found in 12.5%.
- Only 26% of patients had "insignificant" tumors.

The Playing Field Has Changed

- When TRUS biopsy introduced cancers were larger and detectable by both DRE and TRUS
 Today lesions are very small or located in regions that are not discoverable by DRE or TRUS
- This has resulted in the 12-core biopsy being a "semi-blind" procedure.
- Re-biopsy using the same technology does not yield better results

Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations

Ahmedin Jemal, DVM, PhD; Stacey A. Fedewa, MPH; Jiemin Ma, PhD; Rebecca Siegel, MPH; Chun Chieh Lin, PhD; Otis Brawley, MD; Elizabeth M. Ward, PhD



Screening rates 10% 2005-2008 18% 2010-2013

JAMA. 2015;314(19):2054-2061. doi:10.1001/jama.2015.14905

The Centers for Medicare & Medicaid Services (CMS) seeks stakeholder comments on the following clinical quality measure under development:

Title: Non-Recommended PSA-Based Screening

Description: The percentage of adult men who were screened unnecessarily for prostate cancer using a prostate-specific antigen (PSA)-based screening test

Prostate Testing Should Be Up to the Patient

That the U.S. Preventive Services Task Force states that PSA causes "more harm than good" is an unfortunate byproduct of the success of PSA. However, the problem isn't PSA but the biopsy technique used to diagnosis prostate cancer. The solution to this problem is to improve the biopsy test. Investigators are having Wednesday, December 2, 2015


NELSON N. STONE, M.D. New York

Biopsy Approaches

mpMRI
Only identify index lesion and hemi-ablate
TPMB
Ablate individual lesions-targeted focal therapy


Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study

Hashim U. Ahmed ^{a,b,†,*}, Louise Dickinson ^{a,b,†}, Susan Charman ^{c,d}, Shraddha Weir^b, Neil McCartan^b, Richard G. Hindley^e, Alex Freeman^f, Alex P. Kirkham^g, Mahua Sahu^b, Rebecca Scott^a, Clare Allen^g, Jan Van der Meulen^{c,d}, Mark Emberton^{a,b}




Tumor Target Volume for Focal Therapy of Prostate Cancer—Does Multiparametric Magnetic Resonance Imaging Allow for a Reliable Estimation?

F. Cornud,* Gaby Khoury, Naim Bouazza, Frederic Beuvon, Michael Peyromaure, Thierry Flam, Marc Zerbib, Paul Legmann and Nicolas B. Delongchamps



THE JOURNAL OF UROLOGY®



	slope [IC95]	p-value	correlation coefficient	r²
T2W volume	0.94 [0.87-1.01]	0.12	0.88	0.84
DW volume	1.05 [0.98-1.13]	0.16	0.90	0.85
DCE volume	0.65 [0.55-0.76]	<10 ⁻⁴	0.62	0.48


Underestimation in 43/87 (49%) by mean of 0.56 cc (0.005-2.84)

Transperineal Template-Guided Prostate Biopsy and TFT



Transperineal template prostate-mapping biopsies: an evaluation of different protocols in the detection of clinically significant prostate cancer

Massimo Valerio^{* †‡}, Chukwuemeka Anele^{*†}, Susan C. Charman[§], Jan van der Meulen[§], Alex Freeman[¶], Charles Jameson[¶], Paras B. Singh^{**}, Mark Emberton^{*†} and Hashim U. Ahmed^{*†}



N=391

Average number cores 46 BJU International © 2015 BJU International

	Strategy 1	Strategy 2	Strategy 3
Sensitivity (95% CI), %	78 (73–84)	85 (80–90)	84 (79–89)
NPV (95% CI), %	73 (67–80)	80 (74–86)	79 (72–84)

How important is it to know all the pathology in the prostate?
Crawford et at AUA 2016

RP stage was pT2a/b in 4 (16%), pT2c in 13 (52%) and pT3 in 8 (32%). The 2 patients with low volume disease on RP each had 1 core GS 6 with TPMB.
 TPMB correctly identified 100% of the RP patients.

- Skouteris et al
 - Urinary tract infections are 5x more common in TRUS biopsy compared to TPMB


Urinary retention occurred in 7.4% of TPMB and was associated with older age and increased prostate size.

Inadequacy of Current Technology

Biopsy needles designed >30 years ago with limited core size and length
No software that provides real-time tracking, representation and recall
Procurement and registry of pathology is time consuming and error prone

Probability of Detection vs. Tumor Radius (Grid sizes (mm) = 1, 2.5, 5, 10 – 15 gauge needle)


Probability of Detection vs. Tumor Radius





Biopsy Site Editor	
/ol ID: 1 + 🚫 🗙	Linned 12/10/2013 8848 T Bran Basuers 4302202 11:52-45 AM 6 MU-
Probe Angle -12.1 deg	21, Dial Deavers 1327232 11.33.13 API 0 PINZ
Jre Location (X,Y) 5,7	Brk Medical 12 Prog. 113 AM Smm
Ref Start Depth (Z) 2.49 L Ser Length 1.7 L	ML: 1.80<1.80 TIS: 0.7<4.0
er Length 1.7 L	Res / Hz 1/24 Hz 10 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
Tumor 1 Tumor 2	Gan 61 % 9 · · ·
Gleason Value 1 🔹 Gleason Value 1 🔹	Dyn. Range 79 dB 8 8
Gleason Start 0% 🗘 Gleason Start 100% 🗘	Harmonic Off
Gleason End 0% 🔷 Gleason End 100% 🗢	
Preview	
Length inside Prostate: 1.70 cm	
e	
	3 10 0 0 0 0 0 0 0 0
Biopsy Taken (go to next biopsy site)	
verlapping Sites: 18	• Measurements
Min Overlap: 0.01 cm 1% Max Overlap: 0.17 cm 10%	C Enable Outlining
Avg Overlap: 0.05 cm 3%	
Pathology Controls	Changing outlines is currently disabled to more easily edit





Previous Workflow


Day	One	Тwo	Three	Three
Location	Histopathology Lab	Operating Room	Gross Dissection Room	Histopathology Lab
Participants				
Touchpoint		Ju Ju		In In
Action	Kit Creation Input Patient info Print labels Cut Media Sterilize Media	 Table Setup (~2 hours) Prostate Biopsy Procedure Doctor yells Site location Nurse labels Formalin Vial Doctor takes Biopsy Hands Gun to Nurse Nurse rolls Biopsy onto Media Hands second Gun to Doctor Second Nurse places Media+Biopsy into Formalin Vial Second Nurse places Vial into Styrofoam Tray Repeat above for all Biopsy Samples Samples soak in Formalin Vials They soak from 6-72 hours (Avg ~12hrs) 	 Table Setup Tissue Gross Dissection Remove single Vial from Styrofoam Tray Inspect sponge, removing any found Biopsy Remove any Biopsy floating in Formalin Measure length Use Swab to dye entire top of Biopsy Blot off extra dye with lint-less lab wipe Pick up dyed Biopsy and put into acetic acid bath Soak Biopsy in glacial acetic acid to set dye Pick up dyed Biopsy and put into Cassette (3 Biopsies per Cassette, Dyed 3 different colors) Put single Biopsy Sponge into Cassette Place Cassette into Cassette Rack Input data into computer Repeat above for until Cassette Rack is full Place Cassette Rack, with lid, into Tissue Processor Rack may include more than one procedure's Cassettes Tissue Processing Rack can be held in Tissue Processor for up to 72 hours 	 Tissue Embedding Rack is placed into Tissue Embedder compartment Media+Biopsy taken out of Cassette (Placed on Tissue Embedder) Embedding Mold slightly filled with Paraffin Wax Biopsy placed into bottom of Embedding Mold Use metal tamper to gently press Biopsy flat Cassette (without lid) is placed on Embedding Mold Embedding Mold filled with Paraffin Wax (No large bubbles allowed) Mold removed once cooled and hardened Repeat above for each Cassette Tissue Microtomy (Squared off) Sum cuts are taken and placed into water bath Sliced strips are broken apart with Tweezers Slices are placed on slide Repeat above for each Mold Routine H&E Staining Coverslipping Station

Notes




The Biopsy Carrier Concept

A Biopsy Carrier that stays with tissue sample from the OR to the pathology slide.




A Biopsy Carrier Prototype

Non-woven material grabs tissue




Closed:


The carrier is able to be processed, embeddable and sliced on microtome



Backer material is transparent and retains sample







In the Histology Lab

10. Dye tissue with tissue marking ink. This indicates distal and proximal ends

11. Run cassettes through standard tissue processing








CONFIDENTIAL

In the Histology Lab

14. Run slides through standard H&E staining and cover slip



15. Slide is ready to analyze!





Conclusions

- Selection of surveillance candidates can be improved with mpMRI targeted biopsies or TPMB
- Targeted focal therapy (TFT) requires precise location of ALL significant lesions and THEN a roadmap for treatment planning
- The jury is out as the whether some or all lesions need treatment
- Proof of success (lesion eradication) remains elusive.

216T ANNUAL SCOTTEDALE

PROSTATE CANCER SYMPOSIUM 2016

MARCH 10 -13, 2016

THE REAL PROPERTY.

JW MARRIOTT CAMELBACK, INN® SCOTTSDALE RESORT & SPA SCOTTSDALE, ARIZONA